Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 3/20 | 0.52 |
| ▸ | ITGB7 | P26010 | 3/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 6/20 | 0.46 |
| ▸ | CTSK | P43235 | 5/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4648927 | 1.00 | ITGA4 (0.52) | ITGA4ITGB7KLK5CTSSCTSK | |
| SCHEMBL4648164 | 0.89 | ITGA4 (0.50) | ITGA4ITGB7KLK5CTSSCTSK | |
| SCHEMBL4648158 | 0.89 | ITGA4 (0.50) | ITGA4ITGB7KLK5CTSSCTSK | |
| SCHEMBL4648153 | 0.89 | ITGA4 (0.50) | ITGA4ITGB7KLK5CTSSCTSK | |
| SCHEMBL4649226 | 0.88 | ITGA4 (0.54) | ITGA4ITGB7KLK5CTSSCTSK | |
| SCHEMBL919680 | 0.88 | ITGA4 (0.54) | ITGA4ITGB7KLK5CTSSCTSK | |
| SCHEMBL1824118 | 0.86 | ITGA4 (0.56) | ITGA4ITGB7KLK5CTSSCTSK | |
| SCHEMBL30759357 | 0.85 | KLK5 (0.55) | KLK5CTSSCTSKACECTSL | |
| SCHEMBL12028561 | 0.85 | KLK5 (0.55) | KLK5CTSSCTSKACECTSL | |
| SCHEMBL21540449 | 0.84 | ITGA4 (0.51) | ITGA4ITGB7KLK5CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1701933-B1 | NOVEL COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-09-03 | — | — | EP | disclosed |
| US-20070043113-A1 | Novel compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043113-A1 | Novel compounds | VCAM1, ICAM1, EPCAM | ITGA4 762/4885ITGB7 709/4885KLK5 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.